FDA Combo Approvals Could Follow Drug-Eluting Stent Template
FDA should use its approval of drug-eluting stents as the template for combination product approvals, attendees recommended at FDA's drug delivery workshop July 8 in Bethesda, Md
You may also be interested in...
FDA is soliciting feedback on regulatory challenges posed by novel drug and biologics delivery systems, and steps the agency can take to ease the regulatory pathway
Post-marketing commitments for Johnson & Johnson/ Cordis' Cypher sirolimus-eluting stent include close monitoring of labeling changes for Wyeth's sirolimus product Rapamune
FDA's Office of Combination Products plans to issue guidance on postmarketing requirements included in "request for designation" letters